THYNTRA

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Nov 2025 filing date already counts against anyone who files later.

Record

Serial number

99512467

Mark type

Stylized text

Filed

24 Nov 2025

Published for opposition

21 Jul 2026

Attorney of record

Jessica R Manganello

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the prevention and treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biologics in the nature of pharmaceutical preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; In vitro diagnostic preparations for medical use; Antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Medical diagnostic reagents; Diagnostic reagents for medical use; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Reagents for use in diagnostic tests for medical purposes; Diagnostic reagents for medical purposes for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for gene therapy for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Drug delivery agents in the form of intranasal spray (nasal sprays), inhalation (aerosols and dry powers), oral (tables, capsules, liquids), topical (creams, gels, transdermal patches), intravenous, and intrathecal routes that facilitate the delivery of pharmaceutical preparations; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Clinical medical reagents; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes

Owner

• Cogthera, LLC, Brookeville, MD, US
• Cogthera, LLC, Brookeville, MD, US

Prosecution history

• 08 Sept 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
• 08 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
• 21 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 21 Jul 2026 — PUBLISHED FOR OPPOSITION
• 15 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 22 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 22 Jun 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 22 Jun 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 22 Jun 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 28 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 28 Mar 2026 — NON-FINAL ACTION E-MAILED
• 28 Mar 2026 — NON-FINAL ACTION WRITTEN
• 28 Mar 2026 — ASSIGNED TO EXAMINER
• 24 Nov 2025 — APPLICATION FILING RECEIPT MAILED
• 24 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED